[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 204
1. Cassier PA, Thevenet C, Walter T, Baulieux J, Scoazec JY, Bancel B, Adham M, Souquet JC, Ponchon T, Lombard-Bohas C: Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. Eur J Gastroenterol Hepatol; 2010 Sep;22(9):1111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
  • PURPOSE: Patients with cholangiocarcinoma or gallbladder cancer have poor overall prognosis and their management is often complex.
  • PATIENTS AND METHODS: We conducted a retrospective analysis of all cases of biliary tract cancer treated at two academic centers in Lyon, France: 127 cases were identified, 67 underwent primary surgery, 13 of which were deemed unresectable upon surgery and were treated medically; 60 patients received medical treatment only.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biliary Tract Neoplasms / drug therapy. Cholangiocarcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Prognosis. Retrospective Studies. Severity of Illness Index. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20386107.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, Kudo T, Todo S: Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg; 2005 Jun;29(6):728-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma.
  • Intrahepatic cholangiocarcinoma (IHCC) is a rare primary hepatic tumor.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Jun;26(6):687-93 [12053220.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):117-21 [10398897.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):326-9 [11995443.001]
  • [Cites] Hepatol Res. 2004 Jan;28(1):21-29 [14734147.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):301-5; discussion 305-6 [9015175.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):41-7 [9683753.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):585-9 [3722412.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1551-7 [6352003.001]
  • [Cites] Surgery. 2001 Apr;129(4):401-7 [11283529.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):108-16 [10398896.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):871-7; discussion 877-9 [8393652.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2326-32 [10873083.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] Br J Surg. 2002 Dec;89(12):1525-31 [12445060.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1463-6 [11683741.001]
  • [Cites] Gastric Cancer. 2001;4(2):54-9 [11706761.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jun;32(6):206-9 [12110637.001]
  • [Cites] World J Surg. 2001 Jul;25(7):865-9 [11572025.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):679-85 [12095601.001]
  • [Cites] J Am Coll Surg. 2001 Oct;193(4):384-91 [11584966.001]
  • (PMID = 15880276.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, Onishi I, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Kayahara M, Ohta T, Wakayama T, Iseki S, Harada S: Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2. Int J Oncol; 2010 Apr;36(4):793-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.
  • In primary malignant liver tumors, trypsinogen-immunoreactivity was present in 70% of intrahepatic cholangiocarcinoma (ICC) specimens, but absent in hepatocellular carcinoma (HCC) specimens.
  • [MeSH-major] Bile Duct Neoplasms / enzymology. Bile Ducts, Intrahepatic / enzymology. Cell Proliferation. Cholangiocarcinoma / enzymology. Receptor, PAR-2 / metabolism. Trypsin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / enzymology. Carcinoma, Hepatocellular / pathology. Culture Media, Serum-Free / metabolism. Dose-Response Relationship, Drug. Female. Fibroblasts / enzymology. Fibroblasts / pathology. Gabexate / pharmacology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Hep G2 Cells. Humans. Liver Neoplasms / enzymology. Liver Neoplasms / pathology. Male. Middle Aged. RNA, Messenger / metabolism. Serine Proteinase Inhibitors / pharmacology

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198321.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / RNA, Messenger; 0 / Receptor, PAR-2; 0 / Serine Proteinase Inhibitors; 4V7M9137X9 / Gabexate; EC 3.4.21.4 / PRSS1 protein, human; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


Advertisement
4. Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H: A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer; 2007;6(1):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
  • We report a case of Muir-Torre syndrome associated with intrahepatic cholangiocarcinoma, a location not previously described, and associated with a novel missense mutation of the MSH2 gene (c.2026T > C), predicted to disrupt the function of the gene.
  • [MeSH-major] Cholangiocarcinoma / genetics. Cholangiocarcinoma / secondary. Germ-Line Mutation. Liver Neoplasms / genetics. MutS Homolog 2 Protein / deficiency. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. Adenoma / genetics. Adenoma / surgery. Adult. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma / genetics. Carcinoma / surgery. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. DNA Mutational Analysis. DNA Probes. DNA-Binding Proteins. Endometrial Neoplasms / surgery. Female. Humans. Microsatellite Instability. Mutation, Missense. Polyps / surgery. Proline / genetics. Sebaceous Gland Neoplasms / genetics. Sebaceous Gland Neoplasms / surgery. Serine / genetics. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] Arch Dermatol. 1968 Nov;98(5):549-51 [5684233.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):567-72 [15235030.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):896-9 [11221877.001]
  • [Cites] Fam Cancer. 2005;4(3):245-8 [16136385.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1159-63 [8118799.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Clin Genet. 2005 Nov;68(5):442-7 [16207212.001]
  • [Cites] Scand J Gastroenterol. 2005 Apr;40(4):455-9 [16028441.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1112-4 [1310886.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):681-6 [10534628.001]
  • [Cites] EMBO J. 1998 May 1;17 (9):2677-86 [9564049.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • (PMID = 17051350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA-Binding Proteins; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


5. De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, Wolfgang CL, Herman JM, Edil BH, Choti MA, Schulick RD, Nagorney DM, Pawlik TM: Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg; 2010 Jul;252(1):142-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on demographics, primary tumor, and hepatic metastasis characteristics, as well as details of the liver-directed therapy were collected and analyzed.
  • RESULTS: Primary tumor histology included neuroendocrine carcinoma (34.9%), pancreatic ductal adenocarcinoma (33.4%), distal cholangiocarcinoma (8.7%), ampullary carcinoma (7.1%), duodenal carcinoma (4.0%), or other (11.9%).
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma / pathology. Carcinoma, Ductal / pathology. Carcinoma, Neuroendocrine / pathology. Cholangiocarcinoma / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531007.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


6. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR: High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol; 2009 Jan;50(1):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High lifetime risk of cancer in primary sclerosing cholangitis.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) patients are at risk for developing cholangiocarcinoma (CCA) and colorectal carcinoma (CRC).
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / embryology. Cholangitis, Sclerosing / complications. Colorectal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Inflammatory Bowel Diseases / complications. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Factors. Young Adult


7. Kevans D, Zeb F, Donnellan F, Courtney G, Aftab AR: Failed biliary access following needle knife fistulotomy: is repeat interval ERCP worthwhile? Scand J Gastroenterol; 2010 Oct;45(10):1238-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoint was success of repeat ERCP in gaining biliary access without further intervention.
  • Repeat ERCP findings were: choledocholithiasis 46%, pancreatic cancer 15% and cholangiocarcinoma 39%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / surgery. Bile Duct Neoplasms / radiography. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures / methods. Catheterization / methods. Cholangiocarcinoma / radiography. Cholangiocarcinoma / surgery. Choledocholithiasis / radiography. Choledocholithiasis / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Needles. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Surgical Instruments. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20553113.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Hwang DW, Lim CS, Jang JY, Lee SE, Yoon SO, Jeon YK, Uk Lee K, Kim SW: Primary hematolymphoid malignancies involving the extrahepatic bile duct or gallbladder. Leuk Lymphoma; 2010 Jul;51(7):1278-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hematolymphoid malignancies involving the extrahepatic bile duct or gallbladder.
  • Primary hematolymphoid malignancies of the extrahepatic biliary tract are rare tumors.
  • We report five cases of primary hematolymphoid malignancies involving the extrahepatic biliary tract.
  • Although a preoperative diagnosis of primary hematolymphoid malignancy is very difficult to reach because of the rarity of this disease, it should be considered, because, if an accurate diagnosis is made before surgical intervention, chemotherapy is the most appropriate treatment.
  • In limited cases mimicking cholangiocarcinoma and gallbladder cancer, surgical resection followed by chemotherapy has a valid role as reasonable treatment for patients.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20572800.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC: Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine; 2010 Mar;17(3-4):161-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-four patients with a median age of 67 years (range 40-84) with pancreatic cancer (15), colon cancer (6), cholangiocarcinoma (1), esophageal cancer (1) and unknown primary (1) received a total of 116 cycles (median 5 cycles; range 1-17 cycles) over 4 dose levels of capecitabine.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Glycyrrhiza. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paeonia. Pancreatic Neoplasms / drug therapy. Scutellaria baicalensis. Ziziphus

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier GmbH.
  • (PMID = 20092990.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / PHY 906; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Leftwich H, Fang YM, Borgida A, Crombleholme W: Primary sclerosing cholangitis in pregnancy refractory to ursodeoxycholic acid treatment: a case report. J Reprod Med; 2010 Nov-Dec;55(11-12):517-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sclerosing cholangitis in pregnancy refractory to ursodeoxycholic acid treatment: a case report.
  • BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease associated with fibrosis and inflammation of the bile ducts.
  • Its complications include symptoms from pruritis and fatigue to dominant strictures, cholangiocarcinoma and liver failure necessitating liver transplant.
  • [MeSH-minor] Adult. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / drug therapy. Cholangitis, Sclerosing / etiology. Female. Humans. Pregnancy


11. Tarazov PG, Granov DA, Sergeev VI, Polikarpov AA, Polysalov VN, Rozengauz EV: Preoperative portal vein embolization for liver malignancies. Hepatogastroenterology; 2006 Jul-Aug;53(70):566-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: To study effectiveness of preoperative portal vein embolization before extensive hepatic resection in patients with primary or secondary liver malignancies.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Embolization, Therapeutic. Hepatectomy. Liver Neoplasms / therapy. Portal Vein
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995463.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Chaudhary HB, Bhanot P, Logroño R: Phenotypic diversity of intrahepatic and extrahepatic cholangiocarcinoma on aspiration cytology and core needle biopsy: case series and review of the literature. Cancer; 2005 Aug 25;105(4):220-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic diversity of intrahepatic and extrahepatic cholangiocarcinoma on aspiration cytology and core needle biopsy: case series and review of the literature.
  • BACKGROUND: Cholangiocarcinoma (CC) represents approximately 10% of primary liver malignancies and can mimic metastatic adenocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Phenotype. Retrospective Studies


13. Law R, Yerian L, Miller C, Dasarathy S: Multifocal cholangiocarcinoma in an explanted liver allograft following retransplant for recurrent primary sclerosing cholangitis. Trop Gastroenterol; 2010 Oct-Dec;31(4):317-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal cholangiocarcinoma in an explanted liver allograft following retransplant for recurrent primary sclerosing cholangitis.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Liver Transplantation / adverse effects
  • [MeSH-minor] Adult. Cholangitis, Sclerosing / surgery. Fatal Outcome. Humans. Male. Recurrence. Transplantation, Homologous


14. Shinohara ET, Mitra N, Guo M, Metz JM: Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1495-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma.
  • The primary endpoint was overall survival (OS).
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Cholangiocarcinoma / radiotherapy. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. African Continental Ancestry Group. Aged. Aged, 80 and over. European Continental Ancestry Group. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Survivors. Young Adult

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472359.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / PHS HHS / / P30-CAO16520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol; 2005 Dec 1;23(34):8739-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hepatobiliary tumors had a significantly greater tendency to remain confined to the liver than did colorectal cancer metastases.
  • CONCLUSION: The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / therapy. Floxuridine / therapeutic use. Liver Neoplasms / therapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / secondary. Bile Duct Neoplasms / therapy. Cholangiocarcinoma / secondary. Cholangiocarcinoma / therapy. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Combined Modality Therapy. Digestive System Surgical Procedures. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314634.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85684; United States / NCRR NIH HHS / RR / M01RR00042
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine
  •  go-up   go-down


16. Lin ZY, Chuang WL, Chuang YH, Yu ML, Hsieh MY, Wang LY, Tsai JF: Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. J Gastroenterol Hepatol; 2006 Feb;21(2):398-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
  • BACKGROUND: The purpose of this prospective study was to investigate whether amphotericin B (AmB) had any potential role in the systemic chemotherapy of primary hepatic malignancy using cancer cells collected by the authors' method of primary culture.
  • METHODS: The specimens obtained by ultrasound-guided fine-needle aspiration biopsy (22 G) from 15 patients with hepatocellular carcinoma (HCC) and one with cholangiocarcinoma were plated into culture flask without disaggregation by trypsin-ethylenediamine tetra-acetic acid solution.
  • Six patients with HCC and one patient with cholangiocarcinoma (7/16, 44%) had successful culture and the cancer cells at the 4th passage were continuously exposed to therapeutic ranges of epirubicin (0, 0.5, 1.0, 1.5, 2.0 microg/mL) with or without the combination of 2.5 microg/mL AmB for 24 h. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was applied to evaluate the effects of the drugs.
  • RESULTS: Addition of AmB showed no influence on epirubicin cytotoxicity in two patients (one partial resistant HCC and one epirubicin-sensitive cholangiocarcinoma; 25%), augmentation of the epirubicin cytotoxicity in two patients (one total resistant HCC, partial resistant HA 22T/VGH cell line and one epirubicin-sensitive HCC; 37.5%), and decrease of epirubicin cytotoxicity in the remaining three (one partial resistant and two epirubicin-sensitive HCC; 37.5%).
  • CONCLUSIONS: Amphotericin B has a discordant influence on epirubicin cytotoxicity in primary cultured hepatic malignant cells.
  • Application of AmB in the systemic chemotherapy of primary hepatic malignancy should be limited to patients with positive AmB effect evaluated by an in vitro sensitivity test such as the present method.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Culture Techniques. Cell Proliferation / drug effects. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Drug Interactions. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509865.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


17. Zhang C, Tu Z, Du S, Wang Y, Wang Q: Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma. Pathol Oncol Res; 2010 Mar;16(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma.
  • Many investigators have indicated that overexpression and amplification of matrix metalloproteinase 2 (MMP-2) and extracellular matrix metalloproteinase inducer (EMMPRIN) are independent prognostic factors for primary tumors.
  • We studied expression of them in tissues from intrahepatic cholangiocarcinoma (IHCCA) and normal bile ducts, and discussed the occurrence and development of IHCCA.
  • MMP-2 and EMMPRIN expression in primary tumor predicts an unfavorable prognosis in IHCCA, suggesting a crucial role of the two markers in progression of human IHCCA.
  • [MeSH-major] Antigens, CD147 / biosynthesis. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / metabolism. Matrix Metalloproteinase 2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 2003;20(7):621-31 [14669793.001]
  • [Cites] Tumour Biol. 2007;28(5):280-9 [17962725.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 May;3(2):279-83 [15138126.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):359-67 [16792544.001]
  • [Cites] Dis Esophagus. 2006;19(6):482-6 [17069593.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2897-904 [15181074.001]
  • [Cites] J Pathol. 2004 Mar;202(3):341-51 [14991900.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1767-74 [17725804.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):888-91 [10706100.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):138-42 [16601431.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Mar;284(3):L541-7 [12456388.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):565-73 [16475027.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):161-9 [12705637.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):1994-2000 [15372476.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):73-80 [14985463.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Hum Pathol. 2008 May;39(5):710-9 [18329694.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):6063-72 [14671212.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] BMC Cancer. 2006 Oct 26;6:255 [17067385.001]
  • [Cites] APMIS. 2007 Aug;115(8):929-38 [17696949.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1174-84 [17919228.001]
  • [Cites] J Surg Oncol. 2008 Dec 1;98(7):535-9 [18814285.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3422-8 [15161697.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1800-10 [16721788.001]
  • [Cites] Int J Urol. 2006 May;13(5):573-80 [16771728.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):70-5 [18234642.001]
  • (PMID = 19629755.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 136894-56-9 / Antigens, CD147; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


18. Stroescu C, Herlea V, Dragnea A, Popescu I: The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointestin Liver Dis; 2006 Mar;15(1):9-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To study the differences between the hepatocellular carcinoma (HCC) and peripheral type of cholangiocarcinoma (CHC) using cytokeratin (CK) and carcinoembryonic antigen (CEA) expressions and assessing their accuracy on paraffin sections in the differential diagnosis.
  • CONCLUSION: The immunohistochemical expression of CKs and CEA might be considered helpful in addition to other diagnostic criteria for the differential diagnosis of primary carcinomas of the liver, especially in difficult cases.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Keratins / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680226.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


19. Amarapurkar AD, Rege JD, Joshi AS, Vaiphei K, Amarapurkar DN: Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors. Indian J Pathol Microbiol; 2006 Jul;49(3):341-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of hepatocellular carcinoma (HCC) is not always easy on simple hematoxylin and eosin (H&E) stain.
  • The aim of the present study was to determine utility of Hep Par 1 (OCH1E5) in differentiating HCC from metastatic tumors and cholangiocarcinoma.
  • Slides having representative sections were subjected to immunohistochemistry with monoclonal antibody Hep Par 1 (Dako Corp) using avidin biotin technique with primary antibody dilution of 1:40.
  • None of the cases of cholangiocarcinoma showed positivity for Hep Par 1.
  • Hep Par 1 is a useful marker in differentiating HCC from metastaic tumors and cholangiocarcinoma with sensitivity and specificity of 89 % and 97 % respectively and positive predictive value of 96 %.
  • [MeSH-major] Antibodies, Monoclonal. Antibodies, Neoplasm / immunology. Biomarkers, Tumor. Carcinoma, Hepatocellular / pathology. Hepatocytes / immunology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Antigens, Surface / immunology. Biopsy. Cell Differentiation / immunology. Diagnosis, Differential. Humans. Immunohistochemistry. Liver / metabolism. Liver / pathology. Neoplasm Metastasis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001880.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Bangarulingam SY, Bjornsson E, Enders F, Barr Fritcher EG, Gores G, Halling KC, Lindor KD: Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology; 2010 Jan;51(1):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis.
  • Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA).
  • [MeSH-major] Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangitis, Sclerosing / complications. Cholangitis, Sclerosing / diagnosis
  • [MeSH-minor] Adult. Aneuploidy. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Liver Transplantation. Male. Middle Aged


21. Klein WM, Molmenti EP, Colombani PM, Grover DS, Schwarz KB, Boitnott J, Torbenson MS: Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol; 2005 Oct;124(4):512-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver carcinoma arising in people younger than 30 years.
  • Primary liver carcinomas in children and young adults are uncommon and poorly described.
  • We examined primary liver carcinomas in people younger than 30 years and performed immunostains for markers of biliary (cytokeratin [CK] 7, CK19, CD56) and hepatocellular (HepPar) differentiation.
  • We found 23 primary liver carcinomas were found: 13 hepatocellular carcinomas (HCCs), 9 fibrolamellar carcinomas (FLCs), and 1 cholangiocarcinoma.
  • In contrast, a control group of 65 adult HCCs showed less CK7 positivity (24 [37%]; P = .03).
  • HCCs are the most common primary liver carcinoma in children and young adults followed by FLCs.
  • They are morphologically similar to adult HCC, but more likely to be CK7(+).
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Animals. Antigens, CD56 / analysis. Bile Duct Neoplasms / chemistry. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / chemistry. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Immunohistochemistry / methods. Keratin-7. Keratins / analysis. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2005 Oct;124(4):491-3 [16146817.001]
  • (PMID = 16146811.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


22. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M: Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg; 2006 Jul-Aug;10(7):987-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
  • The clinical features of Allen's type C of combined hepatocellular and cholangiocarcinoma (cHCC-CC) are not well known.
  • In this study, we aim to define the clinicopathologic features of cHCC-CC and to evaluate the preoperative diagnosis and surgical treatment results in comparison with those of hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Oct 15;78(8):1671-6 [8859179.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Radiology. 2004 Jan;230(1):135-41 [14631050.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Hepatology. 1993 Nov;18(5):1090-5 [7693572.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):832-4 [10919041.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):37-46 [11223823.001]
  • [Cites] Surg Today. 2002;32(8):742-6 [12181730.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):751-8 [11477591.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):956-64 [7545644.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • (PMID = 16843869.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lei JY, Bourne PA, diSant'Agnese PA, Huang J: Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol; 2006 Apr;125(4):519-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
  • The cytoplasmic staining of thyroid transcription factor (TTF)-1 was analyzed in 86 liver resection specimens, including 40 hepatocellular carcinoma (HCC), 4 metastatic HCC, 20 cholangiocarcinoma, 2 combined hepatocellular-cholangiocarcinoma (CHC), and 20 metastatic carcinoma (MC) specimens with immunohistochemical stains to TTF-1, cytokeratin (CK)19, hepatocyte paraffin 1, alpha-fetoprotein, polyclonal carcinoembryonic antigen, CK7, and CK20.
  • The results suggest TTF-1 cytoplasmic staining, together with CK19, might serve as a useful marker for the diagnosis of primary and metastatic HCC and for the differential diagnosis of HCC from cholangiocarcinoma and MC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Cytoplasm / metabolism. Liver Neoplasms / diagnosis. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627262.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


24. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ: Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl; 2007 Oct;13(10):1372-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma.
  • Liver transplantation after neoadjuvant chemoradiotherapy has emerged as an effective treatment for patients with localized, node-negative, unresectable hilar cholangiocarcinoma (CCA) or CCA arising in the setting of primary sclerosing cholangitis (PSC).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / therapy. Graft Occlusion, Vascular / etiology. Liver Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Graft Survival. Humans. Male. Middle Aged. Neoadjuvant Therapy. Postoperative Complications. Radiotherapy, Adjuvant / adverse effects. Treatment Outcome. Ultrasonography, Doppler, Duplex

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 AASLD.
  • [CommentIn] Liver Transpl. 2007 Oct;13(10):1358-61 [17902140.001]
  • (PMID = 17427173.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI: Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol; 2010 May;45(5):560-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma.
  • BACKGROUND: Reports concerning the clinical usefulness of (18)F 2-fluoro-2-deoxy-D: -glucose integrated positron emission and computed tomography ((18)F-FDG PET-CT) for patients with gallbladder cancer and cholangiocarcinoma are relatively scarce.
  • The purpose of this study was to assess the diagnostic value of PET-CT in relation to a conventional imaging modality, multidetector row CT (MDCT), for patients with gallbladder cancer and cholangiocarcinoma.
  • METHODS: Ninety-nine patients with suspected gallbladder cancer and cholangiocarcinoma who underwent both PET-CT and MDCT for initial staging were included in our study.
  • The results of these two imaging modalities for evaluating primary tumors, regional lymph nodes and distant metastases were compared with the final diagnoses based on pathological or clinical findings.
  • The overall values for the sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs) and the accuracies of PET-CT and MDCT for the detection of a primary tumor were 90.2, 70.6, 93.7, 60.0, 86.9% and 84.2, 70.6, 93.2, 48.0, 81.8%, respectively.
  • PET-CT demonstrated no significant advantage over MDCT for the diagnosis of a primary tumor.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Gallbladder Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Jul 7;13(25):3409-16 [17659686.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54 [12173019.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] Surgery. 1994 Jun;115(6):751-6 [7910985.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] J Hepatol. 2006 Jul;45(1):43-50 [16690156.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4357-68 [15514377.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):819-27 [12933488.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1145-51 [18177454.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] J Comput Assist Tomogr. 2007 Mar-Apr;31(2):223-8 [17414758.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2128-32 [10521954.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(6):432-40 [14714164.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1027-34; discussion 1035-6 [15570208.001]
  • [Cites] Radiology. 2004 Oct;233(1):234-40 [15333766.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):557-69 [10998654.001]
  • [Cites] Radiology. 2002 Nov;225(2):575-81 [12409597.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):527-33 [8799389.001]
  • (PMID = 20035356.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Allam N, Khalaf H, Fagih M, Al-Sebayel M: Liver transplant for hepatocellular carcinoma: experience in a Saudi population. Exp Clin Transplant; 2008 Mar;6(1):14-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant for hepatocellular carcinoma: experience in a Saudi population.
  • OBJECTIVES: We present our experience with deceased-donor liver transplant and living-donor liver transplant for hepatocellular carcinoma.
  • Twenty-three patients had hepatocellular carcinoma (14 deceased-donor liver transplants and 9 living-donor liver transplants).
  • Histopathology revealed incidental cholangiocarcinoma in 2 patients and a hepatoblastoma in 1.
  • Two patients died of primary graft nonfunction within 1 week of the transplant.
  • Three had tumor recurrence at 10, 13, and 18 months after transplant; 2 of these occurred in patients with cholangiocarcinoma.
  • CONCLUSIONS: In our small experience, deceased-donor liver transplant and living-donor liver transplant for hepatocellular carcinoma showed good long-term outcomes.
  • Liver transplant for hepatocellular carcinoma accompanying cholangiocarcinoma had a poor outcome with late tumor recurrence.
  • Use of marginal donors in patients with hepatocellular carcinoma might compromise the outcome in these patients.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cadaver. Child. Child, Preschool. Cholangiocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Graft Survival. Humans. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local. Saudi Arabia. Survival Rate. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405240.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


27. Mizgireuv IV, Revskoy SY: Transplantable tumor lines generated in clonal zebrafish. Cancer Res; 2006 Mar 15;66(6):3120-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors in CB1 fish were induced by N-nitrosodiethylamine (DEN).
  • The histologic analysis of these tumors revealed different types of hepatocellular carcinomas, hepatoblastomas, hepatoma, cholangiocarcinoma, and pancreatic carcinoma.
  • Small pieces of tissue or cell suspensions of either DEN-induced or spontaneous tumors were serially transplanted into the peritoneal cavity of syngeneic fish at different stages of development from 5-day-old larvae to adult fish.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540662.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3IQ78TTX1A / Diethylnitrosamine
  •  go-up   go-down


28. Vrettou E, Hytiroglou P, Sikas N, Soultoyannis I, Goodman ZD: Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives. Virchows Arch; 2005 May;446(5):560-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of primary hepatic carcinoma is reported, which occurred in a 24-year-old woman with a 10-year history of oral contraceptive use, and demonstrated unique morphologic and immunohistochemical features.
  • The neoplastic cells were mostly arranged in trabecular and pseudoglandular growth patterns simulating hepatocellular carcinoma; however, in focal areas, small cystic, organoid and tubular patterns predominated.
  • In conclusion, this unique case may represent a rare variant of cholangiocarcinoma expressing inhibin.
  • [MeSH-minor] Abdominal Pain. Adult. CA-19-9 Antigen / analysis. Carcinoembryonic Antigen / analysis. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Magnetic Resonance Imaging. Nausea. Tomography, X-Ray Computed. Vomiting

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2112-6 [3567872.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):516-24 [9647588.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):144-50 [10202672.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1160-4 [9872645.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):229-34 [9930145.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):591-7 [12808065.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1387-93 [11391527.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2051-5 [1717133.001]
  • (PMID = 15815932.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Contraceptives, Oral, Combined; 0 / KRT7 protein, human; 0 / Keratin-7; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


29. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC: Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn; 2010 Nov;12(6):780-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to determine whether KRAS mutations could be identified in residual pancreatobiliary stricture brushings and to compare the performance characteristics of KRAS mutation analysis to cytology and fluorescence in situ hybridization (FISH) for the detection of carcinoma.
  • Residual brushing cytology cell pellets were retrieved from 132 patients with subsequent clinicopathologic follow-up of cholangiocarcinoma (n = 41), pancreatic adenocarcinoma (n = 35), gallbladder cancer (n = 2), and nonmalignant strictures (n = 54).
  • KRAS mutations and polysomic FISH results were identified in 12 (29%) and 17 (41%) cholangiocarcinoma specimens, with a combined sensitivity of 54% (22/41).
  • KRAS mutations were identified in two patients with primary sclerosing cholangitis, and benign follow-up.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Molecular Diagnostic Techniques. Mutation. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jun 25;93(3):229-35 [11391612.001]
  • [Cites] Gut. 2001 Mar;48(3):403-8 [11171833.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1675-81 [15330900.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):629-35 [10100716.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):412-20 [15467712.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1315-20 [16311354.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Diagn Cytopathol. 2007 Apr;35(4):218-24 [17351944.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] J Clin Gastroenterol. 2007 Nov-Dec;41(10):906-10 [18090159.001]
  • [Cites] Liver Int. 2008 Jan;28(1):12-27 [18031477.001]
  • [Cites] World J Gastroenterol. 2008 Feb 21;14(7):1097-101 [18286693.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):353-360 [18075308.001]
  • [Cites] Oncol Res. 2008;17(4):151-7 [18773859.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1270-8 [18995218.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2180-6 [19232347.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):196-203 [19546608.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):519-27 [19636327.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6 [19501586.001]
  • [Cites] Arch Pathol Lab Med. 2009 Oct;133(10):1600-6 [19792050.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):543-52 [19815694.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):583-9 [19815696.001]
  • [Cites] Pancreas. 2009 Nov;38(8):890-5 [19752775.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):387-92 [10705391.001]
  • [Cites] Diagn Cytopathol. 2002 May;26(5):273-7 [11992366.001]
  • (PMID = 20864634.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2963905
  •  go-up   go-down


30. Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, Lee SA, Hong EK, Lee WJ, Woo SM: Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol; 2010 Jul;17(7):1823-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of intrahepatic cholangiocarcinoma after resection.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy, but the studies for the outcome after resection of ICC are rare.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / mortality. Hepatectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome


31. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW: Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today; 2006;36(10):892-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
  • PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation.
  • We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocellular carcinoma (HCC), and those with cholangiocarcinoma (ICC).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate


32. Okamura Y, Harada A, Maeda A, Fujioka A, Horiba T, Ishigure K, Hirai A, Ito Y, Uesaka K: Carcinomatous meningitis secondary to cholangiocarcinoma without other systemic metastasis. J Hepatobiliary Pancreat Surg; 2008;15(2):237-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous meningitis secondary to cholangiocarcinoma without other systemic metastasis.
  • It occurs in about 5% of all adult cancer patients, though autopsies may double this number.
  • The primary tumors that frequently cause carcinomatous meningitis include lung cancer, breast cancer, leukemia, lymphoma, and melanoma.
  • Carcinomatous meningitis secondary to primary tumors in the gastrointestinal tract is clinically infrequent.
  • In this report, we describe a 73-year-old man with lower bile duct cancer, who developed carcinomatous meningitis following surgical resection of the primary cancer.
  • To our knowledge, this is the third case of carcinomatous meningitis secondary to cholangiocarcinoma described in the literature so far.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / secondary. Meningeal Neoplasms / secondary. Meningitis / etiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392723.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Kloek JJ, van der Gaag NA, Aziz Y, Rauws EA, van Delden OM, Lameris JS, Busch OR, Gouma DJ, van Gulik TM: Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg; 2010 Jan;14(1):119-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma.
  • INTRODUCTION: Controversy exists over the preferred technique of preoperative biliary drainage (PBD) in patients with hilar cholangiocarcinoma (HCCA) requiring major liver resection.
  • RESULTS: Of these patients, 101 (88%) underwent PBD; 90 patients underwent EBD as primary procedure, and 11 PTBD.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Drainage / methods. Preoperative Care
  • [MeSH-minor] Adult. Aged. Catheterization / adverse effects. Endoscopy / adverse effects. Female. Hepatectomy. Humans. Male. Middle Aged. Stents

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):40-6 [11154487.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):41-9 [12838219.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):655-62 [10561089.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):547-53 [11323577.001]
  • [Cites] Gastrointest Endosc. 2009 Jan;69(1):55-62 [18657806.001]
  • [Cites] Endoscopy. 2008 Aug;40(8):625-30 [18680074.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD005444 [18677779.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Aug;6(8):944-950.e3 [18585976.001]
  • [Cites] Eur Radiol. 2008 Mar;18(3):448-56 [17960388.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:127-32 [18081656.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(5):441-6 [17909711.001]
  • [Cites] BMC Surg. 2007;7:3 [17352805.001]
  • [Cites] Am J Surg. 2007 Feb;193(2):149-54 [17236839.001]
  • [Cites] Endoscopy. 2006 Aug;38(8):787-92 [17001568.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):986-95 [16733114.001]
  • [Cites] World J Gastroenterol. 2005 Nov 28;11(44):7024-7 [16437610.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):45-7 [15782991.001]
  • [Cites] Gastrointest Endosc. 1999 Apr;49(4 Pt 1):466-71 [10202060.001]
  • [Cites] Endoscopy. 1998 Oct;30(8):681-6 [9865556.001]
  • [Cites] Gastrointest Endosc. 1998 May;47(5):354-62 [9609426.001]
  • [Cites] Arch Surg. 1995 Jul;130(7):759-63 [7611866.001]
  • [Cites] Endoscopy. 1993 Mar;25(3):213-8 [7686100.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):43-9 [7681018.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Am J Surg. 1989 Apr;157(4):395-9 [2539024.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):57-62 [2439854.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Langenbecks Arch Surg. 2002 Jul;387(3-4):117-24 [12172855.001]
  • [Cites] Radiology. 2002 Oct;225(1):27-34 [12354980.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):185-91 [12578418.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):84-92 [12832969.001]
  • [Cites] J Clin Gastroenterol. 2004 Jul;38(6):518-23 [15220688.001]
  • [Cites] Surg Gynecol Obstet. 1975 Feb;140(2):170-8 [1079096.001]
  • [Cites] N Engl J Med. 1979 Dec 20;301(25):1364-9 [503167.001]
  • [Cites] Gut. 1983 Sep;24(9):845-52 [6604001.001]
  • [Cites] Br J Surg. 1983 Sep;70(9):535-8 [6616158.001]
  • [Cites] Am J Clin Nutr. 1986 Sep;44(3):362-9 [3751957.001]
  • (PMID = 19756881.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ghali P, Marotta PJ, Yoshida EM, Bain VG, Marleau D, Peltekian K, Metrakos P, Deschênes M: Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl; 2005 Nov;11(11):1412-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience.
  • Cholangiocarcinoma is a biliary tumor, which not infrequently complicates primary sclerosing cholangitis.
  • The goal of this retrospective study was to perform a national review of outcomes after liver transplantation in Canadian recipients found to have incidental cholangiocarcinoma in their explanted native liver.
  • Six of the seven liver transplant centers in Canada provided clinical and follow-up information on all liver transplant recipients found to have incidental cholangiocarcinoma in their explants.
  • The diagnosis or suspicion of cholangiocarcinoma prior to transplantation were exclusion criteria for this study.
  • Ten individuals with cholangiocarcinoma were transplanted between 1996 and 2003.
  • In conclusion, although early survival of patients transplanted for incidental cholangiocarcinoma appears good, intermediate- and long-term survival rates are not better than for individuals historically transplanted with known cholangiocarcinoma.
  • Aggressive investigation for cholangiocarcinoma is mandated.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Incidental Findings. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Canada. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Probability. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237695.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R: Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol; 2009 Jun;16(6):1587-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty patients with primary (HCC, n = 17; peripheral cholangiocarcinoma, n = 3) liver malignancies demonstrated findings of radiation lobectomy.
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Carcinoma, Hepatocellular / radiotherapy. Cholangiocarcinoma / radiotherapy. Liver / pathology. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts, Intrahepatic. Embolization, Therapeutic. Female. Humans. Male. Microspheres. Middle Aged. Organ Size / radiation effects. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357924.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


36. Chen PH, Lin YC, Tu HP, Chiang SL, Ko AM, Hsu CL, Chang YF, Ko YC: Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. Eur J Cancer; 2007 Apr;43(6):1076-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area.
  • This study used a large-scale cancer database in determining the survival prognostic factors among primary liver cancer (PLC) subjects.
  • The prognostic indicators associated with higher risk of all-cause deaths are male gender (males versus females; HR=1.16, 95% confidence intervals (CI), 1.13-1.20), diagnosis at later period (shown in 1990-1994 versus 1985-1989; HR=1.04, 95% CI, 1.01-1.08), increasing age at diagnosis, subjects with adenocarcinoma/cholangiocarcinoma (CC) and with no therapy against those with chemotherapy.
  • [MeSH-minor] Adenocarcinoma / mortality. Adult. Age Distribution. Aged. Carcinoma, Hepatocellular / mortality. Cause of Death. Cholangiocarcinoma / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Distribution. Survival Analysis. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329095.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, Tsuneyoshi M: Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol; 2006 Mar;37(3):283-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
  • Combined hepatocellular and cholangiocarcinoma (cHC-CC) is a rare type of liver cancer displaying both hepatocellular and cholangiocellular components.
  • The cholangiocellular carcinoma (CC) in these tumors ranges from focal to prominent.
  • The Ki-67 labeling index values for the hepatocellular carcinoma, CC, and sarcomatous components were 11.4% +/- 12.9%, 25.4% +/- 18.3%, and 46.0% +/- 23.6%, respectively.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / secondary. Cholangiocarcinoma / secondary. Liver Neoplasms / pathology. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasms, Multiple Primary. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613323.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Dubay D, Gallinger S, Hawryluck L, Swallow C, McCluskey S, McGilvray I: In situ hypothermic liver preservation during radical liver resection with major vascular reconstruction. Br J Surg; 2009 Dec;96(12):1429-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seven patients underwent liver trisegmentectomy and two had primary retrohepatic venal caval resection.
  • [MeSH-minor] Adult. Aged. Anticoagulants / therapeutic use. Cholangiocarcinoma / surgery. Hepatic Veins / surgery. Humans. Intraoperative Care. Leiomyosarcoma / surgery. Middle Aged. Neoplasm Recurrence, Local / surgery. Neurilemmoma / surgery. Reoperation. Reperfusion / methods. Tissue Preservation. Tomography, X-Ray Computed. Venae Cavae / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 British Journal of Surgery Society Ltd.
  • (PMID = 19918862.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


39. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


40. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, Wang YL, Li DQ: Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol; 2008 Jan 28;14(4):632-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.
  • AIM: To carry out a hospital-based case-control study to investigate risk factors for intrahepatic cholangiocarcinoma (ICC) in China.
  • The presence of diabetes mellitus, hypertension, hepatolithiasis, primary sclerosing cholangitis, liver fluke infection (Clonorchis sinensis), was investigated through clinical records.
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / epidemiology. Hepatitis B, Chronic / epidemiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. China / epidemiology. Endemic Diseases / statistics & numerical data. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Nov 15;68(10):2217-23 [1655206.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Dec;13(12):881-91 [16491521.001]
  • [Cites] Chin Med J (Engl). 1992 Mar;105(3):209-11 [1395840.001]
  • [Cites] Hepatology. 1995 Nov;22(5):1404-8 [7590655.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] Hepatology. 1997 Feb;25(2):463-9 [9021965.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Dec;14(12):1144-9 [10634149.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):542-50 [11180885.001]
  • [Cites] Intern Med. 2001 May;40(5):382-5 [11393406.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] J Hepatol. 2002 Mar;36(3):321-7 [11867174.001]
  • [Cites] Hepatology. 2002 Aug;36(2):439-50 [12143054.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):285-96 [15017670.001]
  • [Cites] Lab Invest. 2004 May;84(5):629-38 [15048136.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2259-62 [15259077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Nov;80(21):6685-8 [6579553.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):323-8 [1645697.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4971-7 [1654208.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):969-73 [9240138.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):175-80 [9490278.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1998 Jun;19(3):134-7 [10322727.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1505-14 [15619210.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Lab Clin Med. 2006 Feb;147(2):58-66 [16459163.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S75-8 [16461228.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(4):327-35 [1348889.001]
  • (PMID = 18203300.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2681159
  •  go-up   go-down


41. Taweevisit M, Chirakalwasan N, Pumsuk U, Keelawat S, Shuangshoti S: Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):39-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients.
  • OBJECTIVE: To determine distribution of the primary site of metastatic adenocarcinoma to the cervical lymph node in Thai population with histological correlation.
  • RESULTS: Thyroid gland (papillary carcinoma) was the commonest source of tumor (41%), followed by lung (25%), bile duct (17%) and breast (7%).
  • Metastatic cholangiocarcinoma typically produced distinct glandular pattern, and frequently involved the right supraclavicular lymph node.
  • Brush border of the gland-forming tumor cells was a consistent finding in metastatic cholangiocarcinoma, with 100% sensitivity and 97% specificity.
  • CONCLUSIONS: Cholangiocarcinoma represents a significant portion of primary tumor in Thai patients with cervical nodal metastasis.
  • This figure may hold true for countries where bile duct malignancy is endemic, and may be of clinical usefulness in identification of primary cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / secondary. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / pathology. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Thailand. Thyroid Neoplasms / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439070.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


42. Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N: Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg; 2006;13(6):537-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
  • BACKGROUND/PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is an uncommon subtype of primary liver cancer, the clinicopathological features of which have rarely been reported in detail.
  • The presence of cholangiocellular differentiation appeared to worsen the prognosis when compared with pure HCC, although this difference did not reach statistical significance.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Thailand

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139428.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L: Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol; 2009 Jun;40(6):834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization.
  • Little is known about the molecular cytogenetic changes in cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma, and on the prognostic significance of chromosomal imbalances in hepatocellular carcinoma.
  • Seventy-eight cases of primary liver cancer with available median follow-up of 16.5 months, including 49 hepatocellular carcinomas, 22 cholangiocarcinomas, and 7 combined hepatocellular-cholangiocarcinomas, were examined by comparative genomic hybridization.
  • In hepatocellular carcinoma, the most frequent changes were +8q (54%), -8p (54%), and +1q (42%), followed by -6q (35%), -4q (33%), -13q (29%), -14q (25%), -16q (19%), -17p (19%), +17q (17%), and +20q (15%).
  • In comparison, cholangiocarcinoma had more gains, losses, and breakpoints than hepatocellular carcinoma or combined hepatocellular-cholangiocarcinoma, specifically more frequently -6q (91%), -3p (68%), -9p (55%), -14q (55%), -13q (45%), +1q (41%), +7q (36%), +7p (32%), and +8q (32%).
  • Combined losses at 6q and 3p appeared to be highly characteristic for cholangiocarcinoma.
  • In contrast, combined hepatocellular-cholangiocarcinoma shared frequent +1q (71%), +8q (57%), and -8p (57%) with hepatocellular carcinoma, but a tendency for higher numbers of imbalances with cholangiocarcinoma.
  • Cholangiocarcinoma is characterized by combined losses at 6q and 3p and a tendency for chromosomal instability.
  • On the other hand, combined hepatocellular-cholangiocarcinoma may share similar chromosomal changes with both hepatocellular carcinoma and cholangiocarcinoma, as reflected by common hepatocellular carcinoma-like +8q, +1q, and -8p and a tendency for cholangiocarcinoma-like chromosomal instability.
  • In hepatocellular carcinoma, higher number of gains may prove an adverse prognostic parameter.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Comparative Genomic Hybridization. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200581.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, Wang HY: Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int; 2005 Oct;25(5):962-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
  • BACKGROUND/AIM: Expression alteration of Glypican-3 (GPC3) is associated with several malignancies and has been identified as an overexpressed gene in hepatocellular carcinoma (HCC).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Membrane Proteins / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Bile Ducts, Intrahepatic. Diagnosis, Differential. Female. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glypicans. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162153.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPC3 protein, human; 0 / Glypicans; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


45. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC: Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol; 2010 Jan;34(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
  • Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA).
  • These data strongly support a metaplasia-low-grade dysplasia-high-grade dysplasia-carcinoma sequence in PSC-associated CCA, and underscore the known lack of relationship between patient age and PSC duration in the development of CCA.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Cholangitis, Sclerosing / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Metaplasia. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898228.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Yang WL, Zhang XC, Zhang DW, Tong BF: Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2007 Dec;6(6):631-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma.
  • BACKGROUND: Hepatic hilar cholangiocarcinoma can be diagnosed early with the progress in diagnostic imaging, and thus the rate of resection of the tumor has increased markedly.
  • To assess the effectiveness of resection, we reviewed 185 cases of hepatic hilar cholangiocarcinoma diagnosed and treated at our hospital.
  • METHODS: The clinical data of 185 patients with hepatic hilar cholangiocarcinoma who had been treated surgically from 1972 to 2006 were retrospectively analyzed.
  • Primary symptoms included upper abdominal discomfort or pain, anorexia, tiredness, weight loss and progressive jaundice.
  • CONCLUSIONS: Once patients are diagnosed with hepatic hilar cholangiocarcinoma, they should undergo exploratory laparotomy.
  • Resection is the most effective method for the treatment of hepatic hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Drainage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086631.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T: Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat; 2010 Oct;17(10):742-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus.
  • There are several established risk factors for intrahepatic cholangiocarcinoma (ICC), namely primary sclerosing cholangitis, fibropolycystic liver disease, parasitic infection, intrahepatic biliary stones and chemical carcinogen exposure.
  • [MeSH-major] Cholangiocarcinoma / epidemiology. Hepatitis B, Chronic / complications. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Blood Donors. Cohort Studies. Female. Hepacivirus / pathogenicity. Humans. Japan. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Blackwell Publishing Ltd.
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):244-50 [16235981.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1211-6 [16938527.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1016-21 [17324130.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8 [17689296.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):632-5 [18203300.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1716-20 [18557716.001]
  • [Cites] Hepatology. 2009 Jan;49(1):116-23 [19085911.001]
  • [Cites] Br J Cancer. 2009 Jun 2;100(11):1765-70 [19436294.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2259-62 [15259077.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1075-80 [15386355.001]
  • [Cites] Cancer. 1980 May 15;45(10):2663-9 [6155197.001]
  • [Cites] Vox Sang. 1993;65(3):199-203 [7504373.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Feb;91(2):154-61 [8114321.001]
  • [Cites] Semin Liver Dis. 1994 May;14(2):109-14 [8047893.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] J Epidemiol. 1998 Dec;8(5):292-6 [9884479.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • (PMID = 20002305.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC3020326
  •  go-up   go-down


48. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Kim YS, Lee MS, Lee JS, Shim CS: Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol; 2007 Oct;102(10):2164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.
  • We evaluated the usefulness of serum IL-6 in the diagnosis of primary BDC and measured changes in serum IL-6 levels following photodynamic therapy (PDT).
  • METHODS: We prospectively measured serum IL-6 levels in patients with BDC (N = 26: 14 patients treated with PDT, 12 with biliary drainage alone), hepatocelluar carcinoma (HCC, N = 26), and healthy adults (N = 23).
  • [MeSH-major] Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Interleukin-6 / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Female. Humans. Male. Middle Aged. Photochemotherapy. Predictive Value of Tests. Tumor Burden / physiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2008 Apr;103(4):1045; author reply 1045-6 [18397431.001]
  • [CommentIn] Am J Gastroenterol. 2007 Oct;102(10):2171-2 [17897336.001]
  • (PMID = 17617204.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-6
  •  go-up   go-down


49. Lang H, Sotiropoulos GC, Sgourakis G, Schmitz KJ, Paul A, Hilgard P, Zöpf T, Trarbach T, Malagó M, Baba HA, Broelsch CE: Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg; 2009 Feb;208(2):218-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a rare primary liver malignancy.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Disease-Free Survival. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Treatment Outcome


50. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer; 2010 Jan 5;102(1):68-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
  • BACKGROUND: Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment.
  • Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma.
  • METHODS: We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma.
  • The primary end point was the disease control rate at 12 weeks.
  • CONCLUSIONS: Sorafenib as a single agent has a low activity in cholangiocarcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Disease-Free Survival. Drug Eruptions / etiology. Fatigue / chemically induced. Female. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):154-6 [19089671.001]
  • [Cites] Oncologist. 2008 Aug;13(8):845-58 [18695262.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1675-84 [19255327.001]
  • [Cites] CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64 [11760569.001]
  • [Cites] Gut. 2003 May;52(5):706-12 [12692057.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Br J Surg. 1996 Dec;83(12):1712-5 [9038548.001]
  • [Cites] Hepatology. 1998 Dec;28(6):1512-7 [9828214.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):279-81 [15668284.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6771-90 [16170185.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):333-47 [16762510.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Biochem Pharmacol. 2007 May 1;73(9):1308-17 [17266941.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3202-9 [17705089.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48 [18026728.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] Oncologist. 2008 Apr;13(4):415-23 [18448556.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1866-72 [19276272.001]
  • (PMID = 19935794.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2813746
  •  go-up   go-down


51. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer; 2008 Jan 29;98(2):309-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were stratified prospectively into two groups based on location of the primary (gallbladder carcinoma (GBC) or extrahepatic cholangiocarcinoma (ECC) versus intrahepatic mass-forming type cholangiocarcinoma (ICC)).
  • [MeSH-minor] Adult. Aged. Capecitabine. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3560-8 [10550155.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):392-9 [11882761.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):702-4 [12232749.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33 [12422305.001]
  • [Cites] Clin Colorectal Cancer. 2002 May;2(1):54-8 [12453338.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1115-20 [12853355.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1355-63 [14598251.001]
  • [Cites] Ann Oncol. 2004 May;15(5):770-4 [15111345.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):578-86 [15274071.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Anticancer Drugs. 1997 Oct;8(9):876-85 [9402315.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):536-42 [9496944.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1297-8 [9849497.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1152-60 [16505435.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):959-63 [16552439.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii68-72 [16760298.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 [16788161.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • (PMID = 18182984.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361467
  •  go-up   go-down


52. Fortner JG, Fong Y: Twenty-five-year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner. Ann Surg; 2009 Dec;250(6):908-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median survival time in months varied by tumor type: metastatic neuroendocrine (81 months), biliary cancer (cholangiocarcinoma) (63 months), gallbladder cancer (47 months), metastatic colorectal cancer (40 months), and hepatocellular carcinoma (27 months).
  • Patients with diagnoses of hepatocellular carcinoma, cholangiocarcinoma, or other metastases (including neuroendocrine tumors or sarcomas) continued to recur and die of disease.
  • CONCLUSION: Liver resection can be performed with long-term survival and potential curative outcome in a variety of primary and metastatic cancers of the liver.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Follow-Up Studies. Humans. Infant. Middle Aged. New York / epidemiology. Prognosis. Retrospective Studies. Survival Rate / trends. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855260.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C: Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg; 2009 Jun;33(6):1247-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Hepatectomy / methods. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Longitudinal Studies. Male. Middle Aged. Multivariate Analysis. Prognosis. Risk Factors. Survival Rate. Treatment Outcome


54. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • Sixteen examples are reported; 3 primary tumors were hilar cholangiocarcinomas, 5 common bile duct carcinomas, and 8 gallbladder carcinomas.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Colloid-type carcinoma was observed at least focally in 3 tumors.
  • Nonmucinous carcinomatous components included adenocarcinoma with high-grade endometrioid-like morphology in 2 cases, papillary adenocarcinoma simulating mixed müllerian epithelial adenocarcinoma in 1, and undifferentiated carcinoma in 2.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts, Extrahepatic. Cholangiocarcinoma / pathology. Cholangiocarcinoma / secondary. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res; 2007 Feb 1;13(3):902-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We examined the infiltration of FOXP3+ Tregs and CD8+ T cells in the tumor stroma and nontumorous liver parenchyma using 323 hepatic nodules including precursor lesions, early hepatocellular carcinoma (HCC), and advanced HCC, along with 39 intrahepatic cholangiocarcinomas and 59 metastatic liver adenocarcinomas.
  • Regardless of the presence of hepatitis virus infection or histopathologic evidence of hepatitis, the prevalence of Tregs was significantly increased in nontumorous liver bearing primary hepatic tumors.
  • It has been suggested that primary hepatic cancers develop in liver that is immunosuppressed by a marked infiltration of Tregs.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Forkhead Transcription Factors / biosynthesis. Liver Neoplasms / metabolism. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD8-Positive T-Lymphocytes / metabolism. Cholangiocarcinoma / metabolism. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289884.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


56. Suksumek N, Leelawat K, Leelawat S, Russell B, Lek-Uthai U: TaqMan real-time PCR assay for specific detection of Opisthorchis viverrini DNA in Thai patients with hepatocellular carcinoma and cholangiocarcinoma. Exp Parasitol; 2008 Jun;119(2):217-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TaqMan real-time PCR assay for specific detection of Opisthorchis viverrini DNA in Thai patients with hepatocellular carcinoma and cholangiocarcinoma.
  • The aim of this study was to develop TaqMan real-time PCR assay that detected Opisthorchis viverrini DNA from 18 normal and 18 tumor tissue specimens from Thai patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), who underwent liver resection from October 2005 to May 2006.
  • Control liver specimens were seven non-primary liver cancers.
  • [MeSH-major] Bile Duct Neoplasms / parasitology. Carcinoma, Hepatocellular / parasitology. Cholangiocarcinoma / parasitology. Liver Neoplasms / parasitology. Opisthorchiasis / diagnosis. Opisthorchis / isolation & purification
  • [MeSH-minor] Adult. Aged. Animals. Case-Control Studies. Computer Systems. DNA Probes. DNA, Helminth / isolation & purification. Female. Humans. Liver / parasitology. Male. Middle Aged. Polymerase Chain Reaction / methods. Risk Factors. Thailand / epidemiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329641.001).
  • [ISSN] 1090-2449
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA, Helminth
  •  go-up   go-down


57. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, Clavien PA: Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol; 2006 Jul;45(1):43-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.
  • PET/CT and ceCT provided a comparable accuracy for the primary intra- (n=14) and extra-hepatic cholangiocarcinomas (n=33).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Reproducibility of Results. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690156.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O: Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):842-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is a rare disease, and large-scale report of PSC in France is lacking.
  • At entry, 11 patients had a diagnosis of hepatobiliary or colon malignancy (cholangiocarcinoma: n = 5, hepatocellular carcinoma: n = 2, gallbladder carcinoma: n = 1 and colorectal cancer: n = 4).
  • RESULTS: During follow-up [3.9 (0.1-7.2) years], colorectal cancer was diagnosed in four patients and biliary carcinoma in two (incidences: 0.76 and 0.38 for 100 patient-years, respectively).
  • Main causes of death (n = 10) were cancer (n = 5, including three colorectal cancers and two cholangiocarcinoma) or liver failure (n = 4).
  • However, the low incidence of cholangiocarcinoma is compatible with a potential chemoprotective effect of UDCA against biliary neoplasia development.
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / drug effects. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / drug therapy. Cohort Studies. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Female. France / epidemiology. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / drug therapy. Humans. Incidence. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Transplantation. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome. Ursodeoxycholic Acid / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779305.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


59. Jung Y, McCall SJ, Li YX, Diehl AM: Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Hepatology; 2007 May;45(5):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis.
  • Hedgehog (Hh) activity has been demonstrated in human cholangiocarcinoma and hepatocellular carcinoma lines, and in myofibroblasts and progenitors from adult rodent livers.
  • We evaluated Hh pathway involvement in the response to biliary injury in primary biliary cirrhosis (PBC).
  • CONCLUSION: This is the first direct evidence that noncancerous, adult human livers harbor several types of cells that produce and/or respond to Hh ligands.
  • [MeSH-minor] Adult. Cell Proliferation. Humans. Immunohistochemistry. Kruppel-Like Transcription Factors / biosynthesis. Nuclear Proteins / biosynthesis. Receptors, Cell Surface / biosynthesis

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464985.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / 5R01-AA010154-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI2 protein, human; 0 / Hedgehog Proteins; 0 / IHH protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


60. Nagaoka S, Itano S, Ishibashi M, Torimura T, Baba K, Akiyoshi J, Kurogi J, Matsugaki S, Inoue K, Tajiri N, Takada A, Ando E, Kuromatsu R, Kaida H, Kurogi M, Koga H, Kumashiro R, Hayabuchi N, Kojiro M, Sata M: Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int; 2006 Sep;26(7):781-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings.
  • BACKGROUND/AIMS: This study aimed to evaluate the usefulness of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (PET) and PET plus computed tomography (CT) fusion images for the detection of extrahepatic metastases of hepatocellular carcinoma (HCC) and combined hepatocellular and cholangiocarcinoma (combined HCC/CC).
  • [MeSH-major] Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Intrahepatic / radionuclide imaging. Carcinoma, Hepatocellular / radionuclide imaging. Cholangiocarcinoma / radionuclide imaging. Liver Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography. Positron-Emission Tomography. Predictive Value of Tests. Sensitivity and Specificity. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911459.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A: The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol; 2007 Jun;19(6):487-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
  • BACKGROUND/AIMS: Cholangiocarcinoma represents a serious complication of primary sclerosing cholangitis.
  • Ursodeoxycholic acid may possibly influence the incidence of cholangiocarcinoma in man.
  • The aim of this study was to evaluate the incidence rate of cholangiocarcinoma in a large group of primary sclerosing cholangitis patients after long-time treatment with ursodeoxycholic acid.
  • PATIENTS AND METHODS: From May 1987 up to May 2005 a total of 150 patients with primary sclerosing cholangitis but without evidence of cholangiocarcinoma at entry were included in the study.
  • Altogether five patients developed a cholangiocarcinoma during treatment yielding a rate of 3.3%.
  • The patients developed 0.58 cholangiocarcinoma per 100 patient-years in years 0-2.5, 0.59 cholangiocarcinoma in years 2.5-8.5, and no cholangiocarcinoma thereafter up to 18 years after entry into the study.
  • The Kaplan-Meier estimate of cholangiocarcinoma incidence during ursodeoxycholic acid treatment reached a plateau after 8.3 years.
  • SUMMARY AND CONCLUSION: The annual incidence rate of cholangiocarcinoma in primary sclerosing cholangitis treated with ursodeoxycholic acid is lower than expected and decreases with time of treatment.
  • [MeSH-major] Bile Duct Neoplasms / chemically induced. Bile Ducts, Intrahepatic / drug effects. Cholagogues and Choleretics / adverse effects. Cholangiocarcinoma / chemically induced. Cholangitis, Sclerosing / drug therapy. Ursodeoxycholic Acid / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cholestasis, Intrahepatic / etiology. Female. Humans. Long-Term Care / methods. Male. Middle Aged. Patient Dropouts. Prospective Studies

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489059.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


62. Awadallah NS, Chen YK, Piraka C, Antillon MR, Shah RJ: Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am J Gastroenterol; 2006 Feb;101(2):284-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for cholangioscopy in patients with primary sclerosing cholangitis?
  • OBJECTIVES: Assess the role of cholangioscopy in primary sclerosing cholangitis for 1) detection of cholangiocarcinoma using cholangioscopy-assisted biopsy 2) detection of stones not seen on cholangiography 3) stone removal with cholangioscopy-directed lithotripsy.
  • HISTOLOGY: positive for extrahepatic cholangiocarcinoma (N = 1), negative/atypical (N = 31), and inadequate (N = 1).
  • Eight patients have undergone transplant and cholangiocarcinoma was present in the explant of two at 1 and 12 months post-cholangioscopy, respectively.
  • CONCLUSIONS: This is the first series of patients with primary sclerosing cholangitis undergoing cholangioscopy for the evaluation of dominant strictures and cholangioscopy-directed stone therapy with demonstrable clinical benefits.
  • Despite the use of cholangioscopy, diagnosis of cholangiocarcinoma remains technically challenging.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / diagnosis. Biopsy. Cholangiocarcinoma / diagnosis. Cholelithiasis / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454832.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hong CK, Yang JM, Kang BK, Kim JD, Kim YC, Chang UI, Yoo JY: A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis. Korean J Intern Med; 2007 Dec;22(4):283-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis.
  • Combined hepatocellular-cholangiocarcinoma is a rare form of primary liver cancer showing features of both hepatocellular and biliary epithelial differentiation.
  • We report here on a case with collision tumor, which apparently was the coincidental occurrence of both hepatocellular carcinoma and cholangiocarcinoma underlying schistosomiasis.
  • Partial lobectomy was performed and we histologically identified the concurrent occurrence of hepatocellular carcinoma and cholangiocarcinoma, (a "collision type carcinoma").
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Schistosomiasis / physiopathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Female. Humans

  • Genetic Alliance. consumer health - Schistosomiasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):317-24 [10711445.001]
  • [Cites] Gut. 2000 Nov;47(5):721-7 [11034592.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2648-55 [11555575.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):235-44 [11580146.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1747-55 [6089997.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Am J Pathol. 1987 Jun;127(3):530-7 [2438941.001]
  • [Cites] Pathol Res Pract. 1987 Dec;182(6):783-91 [2449680.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):187-97 [2449824.001]
  • [Cites] J Pathol. 1988 Dec;156(4):305-10 [2465399.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):280-8 [1847609.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Am J Clin Pathol. 1987 Feb;87(2):168-73 [3028121.001]
  • (PMID = 18309689.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687661
  •  go-up   go-down


64. Talwalkar JA, Lindor KD: Primary sclerosing cholangitis. Inflamm Bowel Dis; 2005 Jan;11(1):62-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sclerosing cholangitis.
  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts.
  • Important complications from PSC include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma.
  • [MeSH-minor] Adult. Biopsy. Cholangiography. Diagnosis, Differential. Female. Humans. Incidence. Liver Transplantation. Male. Pregnancy. Pregnancy Complications. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674115.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 198
  •  go-up   go-down


65. Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM: Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol; 2006 Nov;30(11):1454-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most patients undergoing OLT for chronic biliary tract disease have end-stage liver disease associated with cirrhosis, but a minority are transplanted in the precirrhotic stage for indications that can include poor quality of life (eg, intractable pruritus or fatigue), recurrent ascending cholangitis, or cholangiocarcinoma.
  • The following clinical data were recorded: age, sex, type of biliary tract disease, radiology, clinical symptoms, signs of portal hypertension, pretransplant shunting procedures, time between diagnosis and OLT, and primary indication for OLT.
  • Underlying biliary tract disease included primary sclerosing cholangitis (18 cases), primary biliary cirrhosis (5 cases), autoimmune cholangitis (2 cases), and secondary sclerosing cholangitis (1 case).
  • Primary indications for OLT were recurrent cholangitis and/or decreased quality of life (11 cases), complications of portal hypertension (6 cases), portal hypertension plus cholangitis/decreased quality of life (5 cases), and malignancy (4 cases).
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Hyperplasia. Liver / blood supply. Liver Neoplasms / surgery. Male. Middle Aged. Quality of Life


66. Tischoff I, Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy]. Zentralbl Chir; 2007 Aug;132(4):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
  • Primary liver cancer is one of the most common cancer worldwide.
  • Beside hepatocellular carcinoma (HCC), accounting for more than 80%, cholangiocarcinoma (CC) is the second most frequent primary malignant epithelial liver tumor.
  • Combined hepatocellular-cholangiocarcinoma (HCC/CC) is a rare form of liver cancer with a frequency of 1%.
  • Both, hepatocellular carcinoma and cholangiocarcinoma, show a wide geographical variation with low-incidence areas in North America and Europe and high incidence areas in Africa and Asia.
  • 70-80% of hepatocellular carcinoma occur in cirrhotic liver.
  • The etiology of cholangiocarcinoma remains unclear, most occur in absence of known etiological factors.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Liver Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidence. Liver / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724632.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


67. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol; 2008 Feb;13(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
  • BACKGROUND: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease.
  • METHODS: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10):1301-11 [15376305.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1843-52 [16767220.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):986-91 [9744316.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1392-3 [12176410.001]
  • [Cites] Radiology. 2004 Jan;230(1):300-1; author reply 301-2 [14695404.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1420-5 [15770715.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):226-30 [9705862.001]
  • [Cites] Transpl Int. 2005 Jan;18(1):89-94 [15612989.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Liver Transpl. 2001 Jun;7(6):473-84 [11443573.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):789-93 [15868910.001]
  • [Cites] Acta Oncol. 2005;44(5):496 [16118084.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3818-22 [16799623.001]
  • (PMID = 18307022.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


68. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors


69. Poggi G, Pozzi E, Riccardi A, Tonini S, Montagna B, Quaretti P, Tagliaferri B, Sottotetti F, Baiardi P, Pagella C, Minoia C, Bernardo G: Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver. Anticancer Res; 2010 Dec;30(12):5159-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver.
  • BACKGROUND: Image-guided transcatheter hepatic chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma (HCC) and for adequate preservation of liver function.
  • Among the patients, 123 had hepatocellular carcinoma, 10 had intrahepatic cholangiocarcinoma and 37 had hepatic metastases.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / adverse effects. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization / adverse effects. Catheterization / methods. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187505.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


70. Björnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P: The natural history of small-duct primary sclerosing cholangitis. Gastroenterology; 2008 Apr;134(4):975-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of small-duct primary sclerosing cholangitis.
  • BACKGROUND & AIMS: The long-term prognosis of patients with small-duct primary sclerosing cholangitis (PSC) remains incompletely characterized.
  • One patient with small-duct PSC who progressed to large-duct PSC was diagnosed with cholangiocarcinoma but after progression to large-duct PSC; 20 patients with large-duct PSC developed cholangiocarcinoma.
  • Cholangiocarcinoma does not seem to occur in patients with small-duct PSC, unless the disease has progressed to large-duct PSC.
  • [MeSH-minor] Adult. Cause of Death / trends. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Disease Progression. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Male. Middle Aged. Norway / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Survival Rate / trends. Sweden / epidemiology. Time Factors. United States / epidemiology


71. Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Van Steenbergen W: Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol; 2005 Aug;43(2):358-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
  • [MeSH-major] Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Intrahepatic / radionuclide imaging. Cholangiocarcinoma / radionuclide imaging. Cholangitis, Sclerosing / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975687.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


72. Clemente G, De Rose AM, Giordano M, Mele C, Vellone M, Ardito F, Murazio M, Giuliante F, Giovannini I, Nuzzo G: [Primary intrahepatic lithiasis: indications and results of liver resection]. Chir Ital; 2009 May-Jun;61(3):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intrahepatic lithiasis: indications and results of liver resection].
  • The aim of this study was to review a series of patients submitted to hepatectomy for primary intrahepatic lithiasis to evaluate early and late results with an assessment of indications, methods and long-term outcomes.
  • From January 1992 to December 2007, 40 patients (25 males and 15 females with a mean age of 51 years) underwent surgery for primary intrahepatic lithiasis in our Hepato-biliary Surgery Unit.
  • A cholangiocarcinoma was found in 4 patients (10%) and only two of these underwent liver resection, while an exploratory laparotomy was performed in the remaining two patients for an unresectable tumour, unexpected before surgery.
  • Primary intrahepatic lithiasis is diagnosed increasingly in Western countries as a result of the improvement in imaging techniques.
  • Biliary pain and cholangitis are the most common presenting symptoms, whereas cholangiocarcinoma represents the unfavourable complication of the disease.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Cholestasis, Intrahepatic / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallstones.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694228.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


73. Yan LN, Chen XL, Li ZH, Li B, Lu SC, Wen TF, Zeng Y, Yiao HH, Yang JY, Wang WT, Xu MQ: Perioperative management of primary liver cancer. World J Gastroenterol; 2007 Apr 7;13(13):1970-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative management of primary liver cancer.
  • AIM: To minimize the complications and mortality and improve the survival in primary liver cancer (PLC) patients undergoing hepatic resection.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Perioperative Care / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Energy Metabolism / physiology. Female. Humans. Ketone Bodies / blood. Liver / metabolism. Liver / physiopathology. Liver / surgery. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Sep;182(3):265-7 [11587690.001]
  • [Cites] J Physiol Paris. 2001 Jan-Dec;95(1-6):413-6 [11595468.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2000 Jul;38(7):520-2 [11832098.001]
  • [Cites] Medicina (Kaunas). 2004;40(2):127-34 [15007271.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1990 Jun;87(6):1401-9 [2170713.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1990 May;28(5):295-7, 318-9 [2086101.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Jan;37(1):88-92 [16468651.001]
  • [Cites] Chin Med J (Engl). 1992 Aug;105(8):684-8 [1458973.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1994 Jan;32(1):35-6 [8045199.001]
  • [Cites] Am J Epidemiol. 1999 Jun 1;149(11):1010-5 [10355376.001]
  • [Cites] Korean J Gastroenterol. 2005 Apr;45(4):217-26 [15843747.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):63-8 [16368492.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1991 Feb;29(2):84-6, 141 [1650683.001]
  • (PMID = 17461499.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ketone Bodies
  • [Other-IDs] NLM/ PMC4146975
  •  go-up   go-down


74. Margarit C, Escartín A, Bellmunt J, Allende E, Bilbao I: [Peripheral cholangiocarcinoma: results of surgical treatment]. Gastroenterol Hepatol; 2006 Apr;29(4):215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peripheral cholangiocarcinoma: results of surgical treatment].
  • INTRODUCTION: Peripheral cholangiocarcinoma (PC) is an uncommon primary hepatic tumor that represents 10% of hepatic resections for primary malignant tumors in our experience.
  • [MeSH-major] Cholangiocarcinoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584691.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


75. Feisthammel J, Schoppmeyer K, Mössner J, Schulze M, Caca K, Wiedmann M: Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol; 2007 Jun;30(3):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with inoperable intrahepatic cholangiocarcinoma (ICC) or gallbladder cancer (GBC) and no prior chemotherapy were eligible.
  • The primary endpoint was response rate, and secondary endpoints were overall survival (OS), progression-free survival (PFS), and toxicity.
  • [MeSH-minor] Adult. Aged. Female. Folic Acid / therapeutic use. Humans. Male. Middle Aged. Survival Analysis. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551313.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 12001-76-2 / Vitamin B Complex; 7673326042 / irinotecan; 935E97BOY8 / Folic Acid; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


76. Zhang HY, Kong YL, Zhang HY, He XJ, Zhang H, Liu CL, Zhao G, Xiao M, Zhang XD, Feng ZQ: Hepatic portal cholangiocarcinoma: a clinical analysis of 70 cases. Hepatobiliary Pancreat Dis Int; 2008 Aug;7(4):418-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic portal cholangiocarcinoma: a clinical analysis of 70 cases.
  • BACKGROUND: The incidence of hepatic portal cholangiocarcinoma is increasing and it is always associated with poor survival.
  • METHODS: A retrospective analysis was made on 70 patients with hepatic portal cholangiocarcinoma admitted between January 2004 and February 2007 to the General Hospital of Air Force PLA.
  • RESULTS: Forty-seven patients had hepatic duct-jejunum anastomosis after resection of hepatic portal cholangiocarcinoma.
  • CONCLUSION: Surgery is the primary therapeutic method for hepatic portal cholangiocarcinoma.
  • [MeSH-major] Anastomosis, Roux-en-Y. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Cholangiocarcinoma / surgery. Drainage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693179.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


77. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol; 2005 Aug 14;11(30):4661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue.
  • AIM: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.
  • METHODS: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.
  • CONCLUSION: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Liver Cirrhosis / metabolism. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin-1
  • [Other-IDs] NLM/ PMC4615407
  •  go-up   go-down


78. Granov DA, Ten VP, Rasskazov AK, Pozharskiĭ KM: [Angiogenetic features in liver carcinoma and their prognostic value: clinical and immunohistochemical study]. Arkh Patol; 2006 Nov-Dec;68(6):6-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiogenetic features in liver carcinoma and their prognostic value: clinical and immunohistochemical study].
  • Survival rates were studied in 57 patients with primary liver carcinoma (including 32 with hepatocellular carcinoma [HCC] and 25 with cholangiocellular carcinoma [CCC] in relation to the histological type of a tumor and its microcirculatory bed.
  • [MeSH-major] Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Neovascularization, Pathologic / mortality. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290884.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


79. Hajdu CH, Murakami T, Diflo T, Taouli B, Laser J, Teperman L, Petrovic LM: Intrahepatic portal cavernoma as an indication for liver transplantation. Liver Transpl; 2007 Sep;13(9):1312-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a predominantly intrahepatic portal cavernoma occurring in a patient with chronic idiopathic portal vein thrombosis, which led to severe cholangiopathy that mimicked primary sclerosing cholangitis and cholangiocarcinoma, was unresponsive to endoscopic stent placement, and finally required liver transplantation.
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Magnetic Resonance Imaging. Male. Stents. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 AASLD.
  • (PMID = 17763385.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W: The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis; 2006 Jul;38(7):490-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To study the dynamic change of hepatocyte growth factor after hepatectomy in patients with primary liver cancer, and to analyse the prognostic value of hepatocyte growth factor and c-met for these patients.
  • Serum hepatocyte growth factor level was positively affected by tumour size, node cirrhosis, portal vein tumour thrombi, cholangiocarcinoma (including combined hepatocellular carcinoma), poorly differentiated hepatocellular carcinoma and tumour recurrence or metastases.
  • C-met protein expression in cancerous tissues was correlated with portal vein tumour thrombi, cholangiocarcinoma and tumour recurrence or metastases, and the expression in paracancerous tissues was correlated with node cirrhosis.
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627020.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


81. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD: Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol; 2010 Jul 20;28(21):3491-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to evaluate the response rate by Response Evaluation Criteria in Solid Tumors (RECIST).
  • PATIENTS AND METHODS: Eligible patients had advanced cholangiocarcinoma or gallbladder cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Cholangiocarcinoma / drug therapy. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / genetics. Vascular Endothelial Growth Factor A / blood

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):584-9 [11506500.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1133-40 [12008203.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):317-9 [15269308.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:308-11 [10436847.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2544-55 [15753462.001]
  • [Cites] Eur J Surg Oncol. 2007 Oct;33(8):1025-9 [17400419.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4743-50 [17909199.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7878-83 [19047117.001]
  • [Cites] N Engl J Med. 2009 Feb 5;360(6):563-72 [19196673.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):843-50 [19139433.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):862-7 [19238628.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):371-7 [19142638.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):138-42 [16601431.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3739-47 [10999768.001]
  • (PMID = 20530271.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CM / N01 CM62205
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2917213
  •  go-up   go-down


82. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK: Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer; 2005 Jan 1;103(1):111-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
  • Of 42 patients, 24 (57%) survived > or = 6 months, satisfying the primary end point of the trial.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Cholangiocarcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558814.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


83. Wu Y, Johlin FC, Rayhill SC, Jensen CS, Xie J, Cohen MB, Mitros FA: Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transpl; 2008 Mar;14(3):279-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma.
  • This retrospective study reviews our experience in surveillance and early detection of cholangiocarcinoma (CC) and in using en bloc total hepatectomy-pancreaticoduodenectomy-orthotopic liver transplantation (OLT-Whipple) to achieve complete eradication of early-stage CC complicating primary sclerosing cholangitis (PSC).
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / radiotherapy. Cholangiocarcinoma / surgery. Hepatectomy / methods. Liver Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Cholangiopancreatography, Endoscopic Retrograde. Cholangitis, Sclerosing / complications. Combined Modality Therapy. Disease-Free Survival. Humans. Middle Aged. Pancreaticoduodenectomy / methods. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306329.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Shinohara ET, Mitra N, Guo M, Metz JM: Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1191-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was overall survival.
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Bile Ducts, Extrahepatic. Cholangiocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Palliative Care. Radiotherapy, Adjuvant / mortality. Retrospective Studies. SEER Program. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201549.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA016520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


85. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, Lee SS, Seo DW, Lee SK: Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol; 2008 May;103(5):1145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
  • OBJECTIVES: This study was conducted to evaluate the clinical role of integrated positron emission and computed tomography (PET-CT) in patients with suspected and potentially operable cholangiocarcinoma.
  • METHODS: Between October 2005 and May 2007, 123 patients with suspected cholangiocarcinoma were enrolled in this study after diagnostic workup, including biliary dynamic computed tomography (CT) and magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) with magnetic resonance (MR) angiography.
  • Patients with overt unresectable cholangiocarcinoma or gallbladder cancer diagnosed via conventional imaging were excluded.
  • RESULTS: The overall values for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET-CT in primary tumor detection were 84.0%, 79.3%, 92.9%, 60.5%, and 82.9%, respectively.
  • PET-CT demonstrated no statistically significant advantage over CT and MRI/MRCP in the diagnosis of primary tumor.
  • According to different morphologic characteristics of cholangiocarcinoma, PET-CT showed no significant difference in detecting those of mass-forming, periductal-infiltrating, and intraductal-growing types.
  • Additional use of PET-CT for assessing resectability correctly showed different results from those determined by conventional imaging in 15 (15.9%) of 94 patients with cholangiocarcinoma.
  • CONCLUSIONS: PET-CT improved the accuracy of preoperative staging in patients with cholangiocarcinoma planning to undergo curative resection.
  • [MeSH-major] Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Extrahepatic / radionuclide imaging. Bile Ducts, Intrahepatic / radionuclide imaging. Cholangiocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Image Processing, Computer-Assisted. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Biopsy. Cholangiopancreatography, Magnetic Resonance. Female. Humans. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radionuclide imaging. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177454.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Tischendorf JJ, Krüger M, Trautwein C, Duckstein N, Schneider A, Manns MP, Meier PN: Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy; 2006 Jul;38(7):665-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
  • BACKGROUND AND STUDY AIMS: Primary sclerosing cholangitis (PSC) is associated with the development of cholangiocarcinoma in up to 10 % of patients.
  • Cholangiography or endoscopic tissue sampling does not reliably distinguish between cholangiocarcinoma and a benign dominant bile duct stenosis.
  • RESULTS: Twelve PSC patients (23 %) had dominant bile duct stenoses caused by cholangiocarcinoma, whereas 41 of the 53 patients (77 %) had benign dominant bile duct stenoses.
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / chemically induced. Bile Duct Neoplasms / complications. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / pathology. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Constriction, Pathologic. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2006 Jul;38(7):743-4 [16810598.001]
  • [ErratumIn] Endoscopy. 2006 Aug;38(8):852
  • (PMID = 16673310.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Strassburg CP: [Autoimmune liver diseases and their overlap syndromes]. Praxis (Bern 1994); 2006 Sep 6;95(36):1363-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From the standpoint of clinical disease three entities can be distinguished: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).
  • In 10-20% PSC is associated with cholangiocarcinoma and also with colon cancer.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Antibodies, Antinuclear / blood. Autoantibodies / blood. Azathioprine / administration & dosage. Azathioprine / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Female. Fluorescent Antibody Technique, Indirect. Genetic Predisposition to Disease. Humans. Immunosuppression. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Liver Transplantation. Male. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Sex Factors

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989180.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Antinuclear; 0 / Autoantibodies; 0 / Immunosuppressive Agents; 9PHQ9Y1OLM / Prednisolone; MRK240IY2L / Azathioprine
  • [Number-of-references] 85
  •  go-up   go-down


88. Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferraioli G: Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol; 2005 Jan;184(1):207-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our objective was to report the complications that occurred in a large series of patients with primary or metastatic liver tumors treated with percutaneous saline-enhanced radiofrequency ablation under sonographic guidance at a single center during 3 years of experience.
  • Of these patients, 287 had hepatocellular carcinoma from cirrhosis, 47 had liver metastases (38 from colon, six from breast, two from lung, and one from cutaneous melanoma), and two had primary cholangiocarcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Postoperative Complications / epidemiology. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Sodium Chloride / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615976.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


89. Morris-Stiff G, Bhati C, Olliff S, Hübscher S, Gunson B, Mayer D, Mirza D, Buckels J, Bramhall SR: Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg; 2008;25(2):126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience.
  • AIM: To report the prevalence and outcome of cholangiocarcinoma arising in primary sclerosing cholangitis for a British tertiary referral centre.
  • METHODS: All patients diagnosed with primary sclerosing cholangitis and concurrent cholangiocarcinoma were identified from a prospectively maintained departmental database, and the mode of presentation, management and outcome were determined.
  • RESULTS: Of 370 patients with primary sclerosing cholangitis, 48 patients (13%) were diagnosed with a cholangiocarcinoma within a median time of 0.51 months (range: 0-73.12) from presentation to the unit.
  • Mode of presentation included: inoperable tumours (n = 14); incidental findings in transplant hepatectomy specimens (n = 13); primary sclerosing cholangitis follow-up (n = 9); transplant work-up (n = 5); transplant waiting list (n = 5); suspected tumour confirmed at transplant (n = 1), and incidental finding at cholecystectomy (n = 1).
  • CONCLUSIONS: Cholangiocarcinoma is a common finding in primary sclerosing cholangitis and regular screening of this cohort of patients at referring centres is advocated to detect early tumours, as surgical treatment at an early stage offers significantly better outcomes for this cohort of patients.
  • [MeSH-major] Cholangiocarcinoma / complications. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / complications. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Female. Hepatectomy. Humans. Liver Transplantation. Male. Middle Aged. Prospective Studies. Stents

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18446034.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T: Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol; 2008 Oct;49(8):855-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.
  • BACKGROUND: Early detection of cholangiocarcinoma (CC) is very difficult, especially in patients with primary sclerosing cholangitis (PSC) who are at increased risk of developing CC.
  • CONCLUSION: With 1H-MRS of bile, cholangiocarcinoma could be discriminated from benign biliary conditions with or without PSC.
  • [MeSH-major] Bile / chemistry. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangitis, Sclerosing / complications. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Acids and Salts / analysis. Biomarkers, Tumor / analysis. Cholesterol / analysis. Diagnosis, Differential. Female. Humans. Lipids / analysis. Male. Middle Aged. Multivariate Analysis. Phosphatidylcholines / analysis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608012.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Lipids; 0 / Phosphatidylcholines; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


91. Hertl M, Cosimi AB: Liver transplantation for malignancy. Oncologist; 2005 Apr;10(4):269-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, liver transplantation for HCC in the adult population yields good results for patients whose tumor masses do not exceed the Milan criteria.
  • Metastatic liver disease is not an indication for liver transplantation, with the exception of cases in which the primary is a neuroendocrine tumor, for which liver transplantation can result in long-term survival and even cure in a number of patients.
  • And finally, while gallbladder cancers are never an indication for liver transplantation, rare cases of cholangiocellular cancer might qualify if aggressive combination therapies, including chemotherapy and radiotherapy followed by OLT, are carried through.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Hemangioendothelioma, Epithelioid / mortality. Hemangioendothelioma, Epithelioid / pathology. Hemangioendothelioma, Epithelioid / surgery. Hepatoblastoma / mortality. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Medical Oncology / trends. Neoplasm Metastasis. Patient Selection. Survival Rate. Treatment Outcome. Waiting Lists


92. Kanemitsu E, Esaki M: A case of intrahepatic cholangiocarcinoma associated with primary sclerosing cholangitis. Jpn J Clin Oncol; 2010 Jun;40(6):600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intrahepatic cholangiocarcinoma associated with primary sclerosing cholangitis.
  • [MeSH-major] Bile Duct Neoplasms / complications. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Adult. Humans. Male


93. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol; 2009 Mar;16(3):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types.
  • PATIENTS AND METHODS: Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor.
  • CONCLUSIONS: Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates.
  • High CA 19-9 level was associated with poorer survival, suggesting that the cholangiocarcinoma portion may be a major determining factor for patient prognosis.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130133.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA: Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg; 2008 Jan;12(1):117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.
  • Cholangiocarcinoma is an aggressive malignancy with 5-year survival rates<15%.
  • Two hundred eighty patients with cholangiocarcinoma treated with OLT from 1987 to 2005 were identified in The United Network for Organ Sharing database.
  • Study variables associated with improved survivals included diagnosis of cholangiocarcinoma pre-OLT [5-year overall survival (OS): 68 vs. 20% for patients with incidental diagnoses at the time of OLT, p<0.001] and OLT after 1993 (5-year OS: 45 vs. 30% pre-1994, p<0.01).
  • In contrast, the diagnosis of concomitant primary sclerosing cholangitis did not impact survivals (5-year OS: 41 vs. 50% without primary sclerosing cholangitis, p=0.402).
  • Selected cholangiocarcinoma patients treated with OLT experience a survival benefit.
  • These data support the continued development of multimodality cholangiocarcinoma treatment protocols that include OLT.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Graft Survival. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate / trends. Time Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Gastroenterol. 2006 May;22(3):294-9 [16550045.001]
  • [Cites] Liver Transpl. 2001 Dec;7(12):1023-33 [11753904.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):201-7 [15192792.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):48-51 [9683754.001]
  • [Cites] Liver Transpl. 2005 Nov;11(11):1412-6 [16237695.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):265-71 [14745336.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):768-71; discussion 771-2 [8273866.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Liver Transpl. 2006 Nov;12(11 Suppl 2):S83-4 [17051566.001]
  • [Cites] Aliment Pharmacol Ther. 2006 May 1;23(9):1287-96 [16629933.001]
  • [Cites] Transplantation. 2000 Apr 27;69(8):1633-7 [10836374.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] Surgery. 2006 Sep;140(3):331-4 [16934588.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Semin Liver Dis. 2006 Feb;26(1):42-51 [16496232.001]
  • [Cites] Liver Transpl. 2006 Nov;12(11 Suppl 2):S15-9 [17051561.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61 [16135931.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):282-7 [14598146.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1703-7 [17198263.001]
  • (PMID = 17963015.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


95. Pozharisskiĭ KM, Granov DA, Ten VP, Kubaĭbergenova AG, Leenman EE, Rasskazov AI: [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers]. Vopr Onkol; 2008;54(4):417-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical investigation used 55 primary hepatic tumors (hepatocellular carcinoma (HCC)--32, cholangiocellular carcinoma (CCC)--23).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / chemistry. Carcinoma, Hepatocellular / diagnosis. Immunohistochemistry. Liver Neoplasms / chemistry. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Calcium-Binding Proteins / analysis. Carcinoembryonic Antigen / analysis. Cholangiocarcinoma / diagnosis. Cyclin A / analysis. Cyclin D. Cyclins / analysis. DNA-Binding Proteins / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Genes, Retinoblastoma. Genes, p53. Humans. Keratin-19. Keratin-8. Ki-67 Antigen / analysis. Male. Microfilament Proteins / analysis. Middle Aged. Neprilysin / analysis. Prognosis. Risk Factors. Survival Analysis. alpha-Fetoproteins / analysis. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942395.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Carcinoembryonic Antigen; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Keratin-19; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Microfilament Proteins; 0 / TTF1 protein, human; 0 / alpha-Fetoproteins; 0 / beta Catenin; 0 / calponin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


96. Chahal P, Baron TH, Poterucha JJ, Rosen CB: Endoscopic retrograde cholangiography in post-orthotopic liver transplant population with Roux-en-Y biliary reconstruction. Liver Transpl; 2007 Aug;13(8):1168-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indication for liver transplant was end-stage liver disease or occurrence of cholangiocarcinoma from primary sclerosing cholangitis in 28 patients and a case each of chronic hepatitis C, alcoholic liver disease, and metastatic islet cell carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Diseases / surgery. Bile Duct Diseases / therapy. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 AASLD.
  • (PMID = 17663414.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Chok KS, Ng KK, Cheung TT, Yuen WK, Poon RT, Lo CM, Fan ST: An update on long-term outcome of curative hepatic resection for hepatocholangiocarcinoma. World J Surg; 2009 Sep;33(9):1916-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatocholangiocarcinoma (HCC-CC) is a rare primary liver cancer.
  • PATIENTS AND METHODS: Prospectively collected data from December 1991 to 2006 recording patients with primary liver cancer receiving curative hepatectomy were reviewed.
  • Their long-term outcome of resection was analyzed and compared to that of patients with cholangiocarcinoma (CC) or hepatocellular carcinoma (HCC).
  • All HCC-CC patients died within 120 months of primary surgery.
  • [MeSH-major] Cholangiocarcinoma / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1995 Feb;130(2):198-203 [7848092.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Hepatol Res. 2005 Jul;32(3):185-95 [15978872.001]
  • [Cites] Br J Surg. 1997 Sep;84(9):1255-9 [9313707.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):280-8 [1847609.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):194-201 [14745327.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):987-98 [16843869.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5 [17374575.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):216-22 [10024103.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):37-46 [11223823.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):322-30 [10077043.001]
  • [Cites] Pathol Res Pract. 1987 Dec;182(6):783-91 [2449680.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • (PMID = 19548027.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Dahl K, Karlsson M, Marits P, Hoffstedt A, Winqvist O, Thörn M: Metinel node--the first lymph node draining a metastasis--contains tumor-reactive lymphocytes. Ann Surg Oncol; 2008 May;15(5):1454-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We previously identified tumor-reactive lymphocytes in the first lymph nodes that drain the primary tumor.
  • The primary tumor site was colorectal cancer in seven patients, malignant melanoma in four, ovarian cancer and breast cancer in two, and one each with pancreatic cancer, cholangiocarcinoma, leiomyosarcoma, and squamous cellular cancer of the tongue.
  • [MeSH-minor] Adult. Aged. Cells, Cultured. Female. Humans. Immunoenzyme Techniques. Immunotherapy. Interferon-gamma / secretion. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Preoperative Care. Prognosis. Radiopharmaceuticals. Rosaniline Dyes. Technetium Tc 99m Sulfur Colloid

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. C.I. FOOD BLUE 3 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):884-91 [15194069.001]
  • [Cites] Contrast Media Mol Imaging. 2006 Nov-Dec;1(6):230-45 [17191764.001]
  • [Cites] Ann Surg. 1969 Mar;169(3):297-9 [5380853.001]
  • [Cites] Prog Exp Tumor Res. 1970;13:1-27 [4921480.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Am J Surg. 1975 Oct;130(4):405-11 [1166931.001]
  • [Cites] Nature. 1980 Jan 10;283(5743):139-46 [6985715.001]
  • [Cites] Br J Cancer. 1983 Jan;47(1):81-9 [6571784.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):381-5 [15837044.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7703-20 [16157938.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):59-70 [16321468.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1490-4 [3978541.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 2):H706-10 [3706547.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Br J Surg. 1992 Jan;79(1):35-8 [1737270.001]
  • [Cites] Ann Thorac Surg. 1995 Dec;60(6):1623-6 [8787454.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9225-9 [15604296.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1142-55 [10971419.001]
  • [Cites] J Urol. 2001 Sep;166(3):812-5 [11490224.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1669-75 [11912138.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Am Surg. 2002 Sep;68(9):745-50 [12356141.001]
  • [Cites] Bioessays. 2002 Nov;24(11):1030-40 [12386934.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):315-9 [12579265.001]
  • [Cites] Surgery. 2003 Mar;133(3):300-8 [12660643.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):413-23 [12872364.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1478-84 [16641897.001]
  • [Cites] Eur Urol. 2006 Jul;50(1):83-91 [16632191.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1362-6 [17088912.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1456-63 [17115389.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):161-6 [15262135.001]
  • (PMID = 18299934.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Rosaniline Dyes; 129-17-9 / patent blue violet; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2277445
  •  go-up   go-down


99. Al-Mashat F, Sibiany AM: Sister Mary Joseph's nodule of the umbilicus: is it always of gastric origin? A review of eight cases at different sites of origin. Indian J Cancer; 2010 Jan-Mar;47(1):65-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors were gastric adenocarcinoma (two patients), ovarian adenocarcinoma (two patients), pancreatic carcinoma (one patient), colonic adenocarcinoma (one patient), gallbladder adenocarcinoma (one patient), and cholangiocarcinoma (one patient).
  • We believe that if the primary cancer is discovered at an early stage, the prognosis may improve.
  • [MeSH-minor] Adult. Colonic Neoplasms / pathology. Female. Gallbladder Neoplasms / pathology. Humans. Male. Middle Aged. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071793.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


100. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • More insight has been gathered recently in the histological classification of hepatocellular adenomas, but the differential diagnosis by imaging of adenoma versus FNH or well-differentiated hepatocellular carcinoma remains often difficult.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down






Advertisement